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Abstract
Although drug induced steatosis represents a mild type of hepatotoxicity it can progress into more severe non-alcoholic
steatohepatitis. Current models used for safety assessment in drug development and chemical risk assessment do not
accurately predict steatosis in humans. Therefore, new models need to be developed to screen compounds for steatogenic
properties. We have studied the usefulness of mouse precision-cut liver slices (PCLS) as an alternative to animal testing to
gain more insight into the mechanisms involved in the steatogenesis. To this end, PCLS were incubated 24 h with the
model steatogenic compounds: amiodarone (AMI), valproic acid (VA), and tetracycline (TET). Transcriptome analysis using
DNA microarrays was used to identify genes and processes affected by these compounds. AMI and VA upregulated lipid
metabolism, whereas processes associated with extracellular matrix remodelling and inflammation were downregulated.
TET downregulated mitochondrial functions, lipid metabolism, and fibrosis. Furthermore, on the basis of the transcriptomics
data it was hypothesized that all three compounds affect peroxisome proliferator activated-receptor (PPAR) signaling.
Application of PPAR reporter assays classified AMI and VA as PPARc and triple PPARa/(b/d)/c agonist, respectively, whereas
TET had no effect on any of the PPARs. Some of the differentially expressed genes were considered as potential candidate
biomarkers to identify PPAR agonists (i.e. AMI and VA) or compounds impairing mitochondrial functions (i.e. TET). Finally,
comparison of our findings with publicly available transcriptomics data showed that a number of processes altered in the
mouse PCLS was also affected in mouse livers and human primary hepatocytes exposed to known PPAR agonists. Thus
mouse PCLS are a valuable model to identify early mechanisms of action of compounds altering lipid metabolism.
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Introduction
Drug induced fatty liver (steatosis) belongs to one of the most
common forms of liver injury [1]. Although benign steatosis does
not severely affect liver function and is reversible, chronic exposure
to steatogenic drugs could lead to the development of steatosis
associated with inflammation, referred to as non-alcoholic
steatohepatitis (NASH). Eventually, NASH can progress to
irreversible liver diseases, including fibrosis, cirrhosis, and liver
cancer requiring liver transplant [2]. To minimize the chances of
developing steatosis and related liver disorders, compounds with
steatogenic properties need to be identified during the early stages
of drug development. In general, steatosis is characterized by
accumulation of vacuoles filled with triglycerides (TG). The exact
molecular triggers resulting in lipid accumulation in the liver are
largely unknown, but may arise from: 1) increased uptake of lipids,
2) elevated de novo lipogenesis, 3) impaired lipoprotein synthesis
and secretion, and/or 4) reduced catabolism of fatty acids (FA) by
peroxisomal/mitochondrial b-oxidation [3]. One of the most
common causes of drug-induced steatosis is impairment of
mitochondrial functions. Mitochondria are essential for energy
generation in the cell through FA b-oxidation, pyruvate oxidation,
and adenosine triphosphate (ATP) synthesis by oxidative phos-
phorylation [4]. Mitochondrial b-oxidation is the major process
that eliminates FA, which accumulate in a form of TG in liver cells
if not-catabolised. Consistent with these notions, many steatogenic
drugs interfere directly with enzymes involved in b-oxidation [4].
Drug-induced perturbations of mitochondrial membranes, tran-
scripts or proteins involved in replication of its DNA could
secondarily impair mitochondrial functions [4]. In addition,
deregulation of lipid metabolism via interactions of drugs with
key regulators of lipid homeostasis, exemplified by members of the
nuclear receptor family such as pregnane X receptor (PXR), liver
X receptor (LXR), or peroxisome proliferator activated receptors
(PPARs), has been reported as well [5]. In particular, alterations in
the expression of PPARa target genes involved in lipid catabolism
(e.g. carnitine palmityltransferase 1 (Cpt1), 3-ketoacyl-CoA thiolase
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(Hadhb), acetyl-Coenzyme A acyltransferase 2 (Acaa2)), have been
linked to the development of drug-induced steatosis [6].
With regard to known steatogenic drugs, the commonly used
antibiotic, tetracycline (TET), inhibits FA catabolism in mice liver
[7–9] and in vitro models, such as cultures of rat and dog
hepatocytes [10–12]. Another example of a steatogenic drug is
amiodarone (AMI). Although AMI is currently approved as an
anti-arrhythmic agent [13], about 18% of patients discontinue
AMI therapy due to undesirable side effects, including develop-
ment of NASH [14]. The steatogenic actions of AMI are related to
inhibition of mitochondrial b-oxidation, paradoxically associated
with upregulation of PPARa target genes involved in lipid
catabolism [15,16]. Valproic acid (VA), next to its beneficial
effects in treatment of epilepsy and bipolar disorder, has been
implicated in drug-induced steatosis. The steatogenic actions of
VA are mainly associated with perturbations in mitochondrial b-
oxidation [17].
Regulation of lipid metabolism in the liver in vivo involves
interaction of both parenchymal (hepatocytes) and non-parenchy-
mal cells (e.g. Kupffer and stellate cells) [18]. Consistent with this
notion, treatment of rat liver in vivo and primary hepatocytes
in vitro with Ppara agonists (fibrates) resulted in significant
upregulation of genes involved in lipid metabolism in both
systems. However, downregulation of genes involved in cellular
morphogenesis, extracellular matrix remodelling, immune re-
sponse and coagulation occurred only in vivo [19]. Therefore,
application of mono-hepatocyte models to study lipid metabolism
does not reflect the entire spectrum of responses characteristic for
the liver in vivo. These shortcomings could be overcome by using
precision cut liver slices (PCLS) that retain native liver architecture
as well as both parenchymal and non-parenchymal cellular
components [20].
In this study, mouse PCLS were used as an in vitro liver model to
investigate mechanisms involved in drug- induced steatosis. The
main goal was to validate PCLS as a tool to identify early
mechanisms of action of three model steatogenic compounds:
TET, AMI, and VA. Transcriptome analysis was combined with
gene reporter assays to substantiate findings related to steatogenic
properties of the selected compounds.
Materials and Methods
Chemicals
AMI, VA, TET, cyclosporin A (CsA), chlorpromazine (CPZ),
ethinyl estradiol (EE), paraquat (PQ), isoniazid (ISND), acetamin-
ophen (APAP) and bovine serum albumin (BSA) were purchased
from Sigma (Sigma, Zwijndrecht, The Netherlands). Williams E
medium (WEM) supplemented with Glutamax, penicillin/strep-
tomycin (pen/strep), D-glucose, phosphate buffered saline (PBS)
were obtained from Invitrogen (Invitrogen, Bleiswijk, The Nether-
lands). GW7647, rosiglitazone, and L165,041 were purchased
from Cayman Chemical (Cayman Chemical, Ann Arbor, MI,
USA). G418-disulfate was obtained from Duchefa Biochemie
(Duchefa Biochemie, Haarlem, The Netherlands).
Preparation and Culture of Liver Slices
Twenty three week-old male C57BL/6 mice from Harlan
(Horst, The Netherlands) were housed for 1 week at 22uC with a
relative humidity of 30–70%. The lighting cycle was 12-h light and
12-h dark. At 24 weeks, the animals were killed with an overdose
of isoflurane, as approved by the Ethical Committee for Animal
Experiments at Wageningen University. Immediately afterwards
the livers were perfused with PBS and placed in ice-cold Krebs–
Henseleit buffer (KHB) (pH 7.4, supplemented with 11 mM
glucose). The tissue was transported to the laboratory within
,30 min and cylindrical liver cores were produced with a surgical
biopsy punch of 5 mm diameter (KAI, SynErgo Europe,
Romania). The cores were placed in a Krumdieck tissue slicer
(Alabama Research and Development, Munford, AL, USA) filled
with ice-cold KHB aerated with carbogen and supplemented with
11 mM glucose. Slices 5 mm in diameter and 0.2 mm in thickness
weighing ,6 mg were prepared. Immediately afterwards, the
slices were transferred to culture plates filled with WEM
Figure 1. Viability of mouse liver slices upon treatment with
steatogenic drugs. Liver slices were incubated for 24 h with
preselected concentrations of amiodarone (AMI) 25, 50, and 100 mM,
valproic acid (VA) 50, 200, and 500 mM, and tetracycline (TET) 5, 40, and
100 mM. ATP content (nmol/mg of protein) in slices treated with
different concentrations of hepatotoxicants was compared to control
slices. Each point is the mean6SD of 5 independent experiments (liver
slices were isolated from livers of 5 mice) and each measurement was
made in duplicate. There were no significant differences between the
tested conditions.
doi:10.1371/journal.pone.0086795.g001
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supplemented with pen/strep at 37uC. Three liver slices were pre-
cultured in one well of the 6-well plate filled with 4 ml of WEM for
1 h with continuous shaking (70 rpm). An oxygen controlled
incubator was used at 80% oxygen, 5% CO2 and the rest was N2.
After 1 h pre-incubation, the medium was removed, refreshed,
and supplemented with the test compounds or their appropriate
solvents. After 24 h incubation, samples were snap-frozen in liquid
nitrogen and stored in 280uC for later analysis. Samples for
histology were fixed in 4% formaldehyde at room temperature.
Cytotoxicity Analysis (Dose Selection)
PCLS were exposed to the different compounds inducing
steatosis, cholestasis, and necrosis, which had been selected based
on published reports. The steatogenic compounds were AMI, VA,
and TET [7,13,17], the cholestatic compounds were represented
by CsA, CPZ, and EE [21–23]. As necrotic agents, PQ, ISND,
and APAP were used [24–26]. To find a non-toxic dose for
subsequent gene expression profiling experiments, the tested
concentration ranges were: CsA 0–100 mM, CPZ 0–80 mM, EE
0–100 mM, AMI 0–100 mM, VA 0–500 mM, TET 0–100 mM,
PQ 0–10 mM, APAP 0–3000 mM and ISND 0–1000 mM. CsA,
CPZ, AMI, PQ, and EE were dissolved in DMSO, VA and TET
were dissolved in ethanol (EtOH), and ISND was dissolved in PBS.
The compounds were added to the culture medium at 0.1% vol/
vol in an appropriate solvent (DMSO, EtOH, or PBS). Slices
incubated with the solvents at 0.1% vol/vol served as controls.
The viability of the slices was assessed by measuring their ATP
content (see below). Doses for the 3 steatogenic compounds were
selected based on 5 independent experiments performed in slices
obtained from livers of 5 mice (Figure 1). Doses for cholestatic and
necrotic drugs were tested in liver slices obtained from 2 mice
(Figure S1) and concentrations that did not decrease the level of
ATP normalized to protein values compared to controls were
selected for final exposure experiments. The selected concentra-
tions for cholestatic and necrotic drugs were tested again in liver
slices obtained from 5 different mice to confirm that they were
non-toxic, Figure S2.
ATP and Protein Measurement
For each ATP and protein measurement a total of 3 co-cultured
slices were placed in 400 mL Cell Lytic MT buffer (Sigma,
Zwijndrecht, the Netherlands). These were homogenized twice
(15 sec, 6500 g, 8uC) using a tissue homogenizer Precellys 24
Bertin Technologies (Labmakelaar Benelux B.V. Rotterdam, The
Netherlands). To remove cellular debris, the homogenates were
centrifuged for 5 min (14000 g, 8uC) and the remaining superna-
tant was divided into 2 portions of 200 mL. One portion was stored
at 280uC for protein measurement and the second 200 mL
Figure 2. Effects of steatogenic drugs on gene expression in mouse PCLS. A. PCLS obtained from 5 mice were treated with 50 mM
amiodarone (AMI), 200 mM of valproic acid (VA), 40 mM of tetracycline (TET) or vehicle for 24 h and subjected to Affymetrix microarray analysis. The
biological processes in the heat map correspond to gene sets significantly affected according to GSEA (p,0.05, FDR,0.05). Processes that were
upregulated are represented by red colour, the downregulated processes are depicted in green, and unaffected processes in black. B. Gene Ontology
(GO) analysis of the significant genes identified by GSEA (p,0.05, FDR,0.05) was performed in DAVID. GO terms were considered to be significant if
p,0.005, FDR,0.005. The significant GO terms were grouped into GO annotation clusters and are depicted as a heat map. For explanation of the
colours see Figure 2A.
doi:10.1371/journal.pone.0086795.g002
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portion was mixed with 100 mL of ATP lytic buffer from ATPlite
kit (Perkin Elmer, Oosterhout, The Netherlands) for ATP
measurement, which was carried out with a microplate reader
Synergy TM HT Multi Detection Microplate Reader (Biotek
Instruments Inc, Abcoude, the Netherlands) with settings for
luminescence: 590/635 nm, top measurement, and sensitivity 230.
ATP was determined in technical duplicates and luminescence
values were recalculated as mM ATP in total liver slice extracts.
Protein concentration was determined by the Bradford method
protein assay (BioRad, Veenendaal, The Netherlands). Protein
samples of 2 mL were diluted 80 times in PBS and measured, with
BSA used as a standard, each measurement being taken in
duplicate. ATP concentration was normalized to mg of protein per
slice.
PCLS Exposure (Gene Expression Profiling)
For transcriptome analysis, PCLS were cultured in the same
conditions as above. Slices were exposed for 24 h to each
concentration of the tested compounds or controls. The concen-
trations used were as follows; for the steatotic exposures: 50 mM
AMI, 200 mM VA, and TET 40 mM. For the cholestatic
exposures: 40 mM CsA, 20 mM CPZ, and 10 mM EE. For the
necrotic compounds: 1000 mM APAP, 1000 mM ISND, and
5 mM PQ. PCLS obtained from 5 mice were used in 5 separate
experiments in which exposure to toxic compound or vehicle were
done simultaneously.
DNA Microarray Hybridizations
Gene expression analysis in PCLS incubated for 24 h was done
on HT Mouse Genome 430 PM array plates using the Affymetrix
GeneTitan system (Affymetrix, Santa Clara, CA, USA). RNA was
Figure 3. Functional clustering of genes involved in energy metabolism (amiodarone). Genes related to energy metabolism identified by
GSEA as being significantly altered upon amiodarone (AMI) treatment were subjected to functional clustering in STRING. Functional clusters such as
lipid synthesis, b-oxidation, mitochondria, peroxisomes, and PPARa -dependent lipid metabolism were identified. Information about fold change
(FC = treatment vs. control) for the analysed genes in individual mice is presented as a heat map. Genes that did not form connected nodes were
removed from the presented clusters. Thicker lines represent stronger associations between genes. Inter-cluster edges are represented by dashed-
lines. The bigger spheres represent genes coding for proteins with known structure. Smaller spheres represent genes coding proteins for which no
structural information is available.
doi:10.1371/journal.pone.0086795.g003
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extracted from 3 slices cultured and exposed together using the
RNeasy Tissue Mini Kit (Qiagen, Venlo, The Netherlands). RNA
concentration and purity were assessed spectrometrically using a
Nano Drop ND-1000 spectrophotometer (Isogen, IJsselstein, The
Netherlands) by measuring absorption ratios at 260/280 and 230/
280 nm. The integrity of the RNA samples was examined using
the Shimadzu MultiNA Bioanalyzer (Shimadzu, Tokyo, Japan).
Biotin- labelled cRNA was generated from high-quality total RNA
with the Affymetrix 39IVT Express Kit with an input of 100 ng
total RNA. The Agilent Bioanalyzer (Agilent, Amstelveen, the
Netherlands) and the Shimadzu MultiNA Bioanalyzer (Shimad-
zu,Tokyo, Japan) were used to assess the quality of cRNA in order
to confirm if the average fragment size was in accordance with the
Affymetrix specifications. Per sample, 7.5 ug cRNA of the
biotinylated cRNA samples was fragmented and hybridized at
0.037 ug/ul on the Affymetrix HT Mouse genome 430 PM arrays.
After automated washing and staining by a GeneTitan machine
(Affymetrix, Santa Clara, CA, USA) using the Affymetrix HWS kit
for Gene Titan, absolute values of expression were calculated from
the scanned array using Affymetrix Command Console v 3.2
software. Data Quality Control was checked with the program
Affymetrix Expression Console v 1.1 software to determine if all
parameters were within quality specifications. The Probe Loga-
rithmic Intensity Error Estimation (PLIER) algorithm method was
used for probe summarisation [27].
In order to monitor the sample-independent control and the
performance of each individual sample during hybridization,
controls were added to the hybridization mixture. The sample-
dependent controls, such as internal control genes, background
values, and average signals, were used to determine the biological
variation between samples. In conclusion, all the data were within
the data Quality Control thresholds, according to Affymetrix
Expression Console specifications. Non-normalized data in a form
of the Cell Intensity File (*.CEL) were re-annotated (EntrezGene
htmg430 pm Mm ENTREZG) and the data were RMA
normalized [27].
All microarray datasets were deposited to Gene Expression
Omnibus (GEO). The GEO series accession numbers are as
Figure 4. Functional clustering of genes involved in energy metabolism (valproic acid). Genes related to energy metabolism identified by
GSEA as being significantly altered upon valproic acid (VA) treatment were subjected to functional clustering in STRING. Functional clusters such as
lipid synthesis, lipid catabolism, b-oxidation, glucose metabolism, and bile acid metabolism have been identified. Information about fold change
(FC = treatment vs. control) for the analysed genes in individual mice is presented as a heat map. For further explanation of the networks see Fig. 3.
doi:10.1371/journal.pone.0086795.g004
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follows: GSE51545 (contain all data used in our study). The GEO
sub-series accession numbers are: GSE51543 (exposures to the
steatogenic compounds), GSE51544 (exposures to the cholestatic
compounds), and GSE51542 (exposures to the necrotic com-
pounds).
Gene Set Enrichment Analysis (GSEA)
To identify differentially expressed gene sets related to diverse
biological functions, Gene Set Enrichment Analysis (GSEA) was
performed with an open access bioinformatics tool (http://www.
broadinstitute.org/gsea/index.jsp). In short, this method identifies
biologically and functionally related genes affected due to
experimental conditions. GSEA applies predefined gene sets based
on the literature or other experiments. Gene sets contain a group
of genes specific for a certain biological process, gene ontology
(GO), pathway, or user defined group. GSEA ranks all the genes
on their expression ratios between a treatment and the control
group, and determines whether a particular gene set is significantly
enriched at the top or the bottom of the ranked list [28]. Gene sets
with p,0.05, FDR,0.05 were considered as significant. Gene sets
used in this study were created in an open access bioinformatics
tool ANNI http://www.biosemantics.org/index.
php?page =ANNI-2-0 [29]. ANNI retrieves all the information
available on known gene-gene associations present in Medline and
can be used, among others, to create gene sets associated with
simple queries, for example ‘‘inflammation’’ or ‘‘cholestasis’’. For
the purpose of this study, we used several queries related to liver
specific and non-specific processes. A summary of the queries used
for the creation of the ANNI gene sets is given in Table S1. Genes
present in at least 5 publications indicating an association with the
specified queries were included in the ANNI gene sets.
Gene sets called ‘‘Wy14643 acute’’ (i.e. 6 hours exposure in
mouse liver in vivo) and ‘‘Wy14643 chronic’’ (i.e. 5 days exposure
in mouse liver in vivo) were also used. These gene sets were derived
from data deposited at Gene Expression Omnibus (GEO):
GSE8292 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc =GSE8292) and GSE8295 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc =GSE8295), respectively. Genes pre-
sent in these gene sets were selected based on analysis done in an
open access bioinformatics tool, Bioconductor 2.12, using Linear
Models for Microarray Data (LIMMA) [30]. A false discovery rate
(FDR) q-value,0.05 and absolute fold change (FC) above 1.6
were applied for identification of significant genes.
Figure 5. Functional clustering of genes involved in energy metabolism (tetracycline). Genes related to energy metabolism identified by
GSEA as being significantly altered upon tetracycline (TET) treatment were subjected to functional clustering in STRING. Functional clusters such as
lipid synthesis, b-oxidation, PPARa signaling, inflammation/apoptosis, amino acids (aa)/glucose/lipid metabolism, and cholesterol/bile acid
homeostasis were identified. Information about fold change (FC= treatment vs. control) for the analysed genes in individual mice is presented as a
heat map. For explanation of the networks see Fig. 3.
doi:10.1371/journal.pone.0086795.g005
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For GSEA, GEO microarray data relevant for actions of known
PPAR agonists in mouse liver in vivo and human primary
hepatocytes were used. To study the effects of PPARs’ agonists
in mouse in vivo following data sets were used: GSE32706
(fenofibrate and fish oil treatments for 14 days; http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc =GSE32706) and
GSE8295 (Wy14673 chronic (5 days) exposure, http://0-www.
ncbi.nlm.nih.gov.elis.tmu.edu. tw/geo/query/ac-
c.cgi?acc =GSE8295). For the action of PPARs’ agonists in
human primary hepatocytes data sets such as GSE33152 (dual
PPARa/c agonists treatment for 6 h, http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc =GSE33152) and GSE17251
(Wy14643 treatment; http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc =GSE17251) were used.
Gene Functional Classification Analysis
The GSEA report output file informs which gene sets are
significantly affected in the analysed experimental groups based on
the enrichment at the top or the bottom of the ranked list of genes
detected on a microarray [28]. In addition, it informs, which genes
in the identified significant gene sets, contribute to this enrichment
based on their ranking position. Thus only genes from the
identified significant gene sets, which are found at the top or at the
bottom of the ranked list, will be assigned by GSEA as genes
contributing to the significant enrichment in the tested gene sets.
Therefore genes, which are not located at the top or the bottom of
the ranked list, are not considered by GSEA as genes that
contribute to the significant enrichment in the tested gene sets. In
the remaining part of this article only genes that were identified by
GSEA as contributing to the significant enrichment in the
identified significant gene sets are referred to as significant genes.
The significantly affected genes by model steatogenic drugs
were uploaded to the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) Bioinformatics Resource, where
the Functional Annotation Clustering tool generated clusters of
overrepresented Gene Ontology (GO) terms [31,32]. The Mouse
Genome, 430 2 PM, was used as a background for the GO
analysis of the mouse PCLS. After correction for false discovery
rate (FDR) #0.005 (Benjamini Hochberg), the GO terms were
selected for further analysis and interpretation.
In addition, we applied another open access data mining tool-
Search Tool for the Retrieval of Interacting Genes/Proteins 8.2
(STRING) to perform gene functional clustering, which was
visualized as networks. STRING constructs these networks using
information from known and predicted protein-protein and gene-
gene interactions present in curated as well as experimental
databases, using statistical algorithms [33]. To construct gene
functional networks in STRING, significant genes identified by
Figure 6. Effect of valproic acid and amiodarone on PPARa, PPAR b/d, and PPARc gene reporter assays. Luciferase activity of PPARa
CALUX cells upon exposure to PPARa agonists: GW7647 (A) and valproic acid (B). Luciferase activity of PPAR b/d CALUX cells upon exposure to PPAR
b/d agonists: L-165, 041 (C), and valproic acid (D). Luciferase activity of PPARc CALUX cells upon exposure to PPARc agonists: rosiglitazone (E),
valproic acid (F), and amiodarone (G). Data are corrected for solvent control values and expressed as means6standard errors (n = 3). X axis represents
concentration of the compounds [M] and y axis represents luciferase units. AMI stands for amiodarone, VA-valproic acid, and TET-tetracycline.
doi:10.1371/journal.pone.0086795.g006
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GSEA in gene sets related to energy metabolism (i.e. glucose
metabolism, lipid metabolism, fatty liver, peroxisomes, mitochon-
drial diseases, and drug metabolism) were used as input to
construct gene functional networks.
Biomarker Identification
To identify biomarkers specific for the steatogenic drugs, the
significant genes found by GSEA in gene sets related to energy
metabolism (i.e. gene sets called glucose metabolism, lipid
metabolism, fatty liver, peroxisomes, mitochondrial diseases, and
drug metabolism) were analysed by Venn diagrams using an open
access online tool http://bioinfogp.cnb.csic.es/tools/venny/index.
html. Genes, which were upregulated (FC$1.5) in PCLS by AMI
and VA, were selected as candidate biomarkers for PPARs
agonists. Genes, which were uniquely downregulated by TET
(FC$21.5), were selected as potential biomarkers for TET-like
acting compounds. Subsequently, expression of the selected genes,
derived from the normalized DNA microarray data, were log2
Figure 7. Identification of potential biomarkers for PPAR agonists in mouse PCLS. PCLS obtained from 4 or 5 mice were exposed for 24 h
to model toxicants for steatosis (amiodarone (A), valproic acid (B), or tetracycline(C)), cholestasis (cyclosporin A (D), chlorpromazine (E), or ethinyl
estradiol (F)), necrosis (acetaminophen (G), isoniazid (H), or paraquat (I)), or controls. GSEA led to the identification of 8 genes upregulated by
amiodarone and valproic acid, which were considered as candidate biomarkers for PPAR agonists. mRNA expression values for the selected
biomarkers are derived from DNA-microarrays and results are presented as heat maps of log2, median centered gene expression values subjected to
HCA. Red and green indicate expression higher and lower, respectively, than the average expression of all samples within the same heat map. AMI
stands for amiodarone, VA-valproic acid, TET- tetracycline, CsA-cyclosporin A, CPZ- chlorpromazine, EE- ethinyl estradiol, APAP-acetaminophen, ISND-
isoniazid, PQ- paraquat, and ctr- controls, M1 represents PCLS obtained from liver of mouse nr 1 etc.
doi:10.1371/journal.pone.0086795.g007
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transformed, median centered, subjected to hierarchical clustering
analysis (HCA), and was presented as heat maps using default
options in Genesis (http://genome.tugraz.at/genesisserver/
genesisserver_description.shtml). To confirm the specificity of the
identified genes as candidate biomarkers for the steatogenic
compounds, their expression was tested in data obtained from
PCLS exposed to different classes of hepatotoxicants i.e.
cholestatic and necrotic compounds. The gene expression found
Figure 8. Identification of potential biomarkers for tetracycline-like acting compounds in mouse PCLS. PCLS obtained from 4 or 5 mice
were exposed for 24 h to model toxicants for steatosis (amiodarone (A), valproic acid (B), or tetracycline (C)), cholestasis (cyclosporin A (D),
chlorpromazine (E), or ethinyl estradiol (F)), necrosis (acetaminophen (G), isoniazid (H), or paraquat(I)), or controls. GSEA led to the identification of 19
genes downregulated by tetracycline (TET) treatment, which were considered as candidate biomarkers for TET-like acting compounds. mRNA
expression values for the selected biomarkers are derived from DNA-microarrays, and results are presented as heat maps of log2, median centered
gene expression values subjected to HCA. For explanation of the colours and abbreviations see Figure 7.
doi:10.1371/journal.pone.0086795.g008
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in PCLS exposed to the cholestatic and the necrotic drugs were
processed as described above for the steatogenic drugs.
PPAR Gene Reporter Assays
PPARa, PPARc and PPARb/d CALUX cell lines were
obtained from BioDetection Systems B.V. (BDS, Amsterdam,
The Netherlands). These are based on human U2-OS cells
Figure 9. Comparative data analysis: relevance for mouse in vivo and human primary hepatocytes. Publically available transcriptomics
data (Gene Expression Omnibus) relevant for the actions of known PPAR agonists in mouse liver in vivo and human primary hepatocytes were used.
The heat map represents significant gene sets (GSEA p,0.05, FDR,0.05), which were subjected to HCA. Gene sets were obtained using the ANNI text
mining tool. Processes that were upregulated are represented by red colour, the downregulated processes are depicted in green, and unaffected
processes are in black. Ale stands for aleglitazar (double PPARa/c agonist), Pio/Feno-pioglitazone/fenofibrate (PPAR c/PPARa agonists), Tesa-
Tesaglitazar (double PPAR c/a agonist), AMI-amiodarone (PPAR c agonist), VA-valproic acid (triple PPARa/(b/d)/c agonist), TET-tetracycline, Wy-
Wy14643, FO-fish oil, m-mouse, h-human, PCLS-precision cut liver slices, PH-primary hepatocytes, L- liver in vivo.
doi:10.1371/journal.pone.0086795.g009
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(American Collection Cell Culture (ATCC), stably transfected
with the relevant human PPAR expression plasmid and a
luciferase reporter construct [34,35] Man et al., unpublished).
All lines were cultured as described before in a 1:1 mixture of
Dulbecco’s modified Eagle’s medium and Ham’s F12 medium
(DF), (Invitrogen, Breda, the Netherlands) supplemented with
7.5% fetal bovine serum (FBS), 1% nonessential amino acids and
(pen/strep) (Invitrogen) [35,36]. Once a week, 200 mg/mL G418-
disulfate was added to the culture medium as a selection pressure
to maintain cells containing the construct. PPAR CALUX was
assayed as before [35,36]. For this, 200 mL of cell suspension in
phenol-free DF supplemented with 5% dextran coated charcoal-
stripped FBS was added to each well of 96-well plates. Test
compounds were added to the culture medium after 24 h. Positive
controls were known agonists of PPARa, PPARc and PPARb/d,
i.e. GW7647, rosiglitazone, and L165,041, respectively. Antago-
nistic activity was tested additionally in the presence of EC50 levels
of agonist, i.e. 3e–9M, 1e–7M, and 8e–8M for GW7647,
L165,041, and rosiglitazone respectively, essentially as before
[35,36]. The threshold for antagonism was set at 10% repression
of agonist activity, in the absence of cytotoxicity. The medium was
removed after 24 h, and the cells were washed and lysed before
luciferase reagent was added and its activity was measured. For
each test compound at last 2 independent experiments were
carried out in triplicate. Luciferase activity per well was measured
as relative light units. Fold induction was calculated by dividing
the mean value of light units from exposed and non-exposed
(solvent control) wells by plotting them in Excel.
Results
Slices Viability
To select one non-cytotoxic drug concentration for the gene
expression profiling studies, PCLS were incubated for 24 h with
model steatogenic compounds (AMI, VA, or TET) at different
concentrations or the corresponding vehicle (control). Viability of
PCLS treated with the drugs was assessed by ATP content
normalized on protein level and compared to control incubations.
There was no dose dependent drug-induced decrease in viability
compared to controls by any of the tested drugs (Figure 1A–C).
For the gene expression profiling studies, 50, 200 and 40 mM for
AMI, VA and TET were applied, respectively, because these
concentrations were non-toxic and similar concentrations had
been used in other studies [37–39].
Transcriptome Data Analysis
To study effect of AMI, VA, and TET on global gene
expression in PCLS, DNA microarray analysis was performed.
The array data were analysed by open access and commercial
bioinformatics tools. Primarily, our interpretation focussed on
assessing effects of steatogenic compounds on general biological
processes, for which gene sets were generated using the literature
data-mining tool, ANNI. In GSEA, we tested in total 47 gene sets
related to general biological processes (e.g. inflammation,
sumoylation, protein folding), hepatic functions (e.g. bile acid
metabolism, cholesterol synthesis, lipid metabolism), and functions
unrelated to liver (e.g. osteogenesis, kidney, brain, heart) (Table
S1). The latter gene sets were included as a negative control. All
significantly altered gene sets were subjected to HCA and are
depicted as a heat map (Figure 2A); unaffected gene sets, including
i.a. kidney, brain and heart, are not shown. Gene sets affected by
AMI and VA shared the most similarities and clustered together.
While gene sets affected by TET clustered apart from AMI and
VA (Figure 2A). The most remarkable differences in AMI- and
VA- versus TET-treated samples were found in gene sets related to
lipid metabolism, fatty liver, and peroxisomes, which were
upregulated by both AMI and VA, and downregulated by TET.
Moreover, AMI and VA treatments downregulated gene sets
related to necrosis, hypoxia, sumoylation, and regulation of T- and
NK- cells functions, while these gene sets were unaffected by TET.
Moreover, only TET-treatment downregulated gene sets related to
other hepatic functions including bile acid metabolism, FA
metabolism, ABC transporters, and cholesterol synthesis
(Figure 2A).
Next, we extracted the significant genes altered in the gene sets
identified by GSEA (p,0.05, FDR,0.05). Within the significantly
enriched gene sets, a total of 774 genes were identified for AMI (93
upregulated and 681 downregulated), 348 genes for VA (45
upregulated and 303 downregulated), and 492 genes for TET (all
downregulated). These genes were uploaded to DAVID for
identification of GO terms. The GO analysis showed a total of
274 (24 upregulated and 250 downregulated), 152 (18 upregulated
and 136 downregulated), and 18 (downregulated) GO terms for
AMI, VA, and TET, respectively (p,0.005, FDR,0.005) (Tables
S2A–C). The identified GO processes were grouped into GO
annotation clusters, which were further analysed by HCA and are
presented as a heat map (Figure 2B). In general, AMI and VA
upregulated GO annotation clusters related to lipid metabolism
and organelles involved in this process (e.g. mitochondrion (AMI)
and peroxisomes (AMI and VA)). Additionally, AMI and VA
downregulated several GO annotation clusters affiliated to
immune functions, extracellular matrix, and development
(Figure 2B). TET downregulated GO clusters related to
mitochondrion and processes localized in this organelle, such as
electron carrier activity (Figure 2B).
A similar type of analysis, using all the significant genes and
individual GO terms, was performed by means of Venn diagrams.
These results were in line with GSEA and GO annotation clusters
analysis and showed that the biggest overlap was for AMI and VA,
followed by a lower number of similarities between AMI and
TET, and the least similarities were observed between VA and
TET (Figure S3 A–B).
In a further analysis, we focused on significant genes identified
by GSEA in gene sets related to energy metabolism (p,0.05,
FDR,0.05). To this end, for each of the 3 treatments, significant
genes were extracted from selected gene sets, i.e. glucose
metabolism, lipid metabolism, fatty liver, peroxisomes, mitochon-
drial diseases and drug metabolism. These genes were uploaded to
STRING for functional clustering, which resulted in the gener-
ation of distinct networks for each drug. However, both AMI and
VA upregulated several genes, which grouped into processes
related to lipid metabolism. AMI upregulated gene functional
clusters related to Ppara-dependent lipid metabolism, b-oxidation,
peroxisomes, mitochondria and lipid synthesis (Figure 3). The
network generated for VA contained gene clusters such as lipid
synthesis, lipid catabolism, b-oxidation, glucose metabolism and
bile acid metabolism (Figure 4). In contrast to AMI and VA, TET
downregulated functional clusters related to lipid synthesis, b-
oxidation, Ppara signaling, inflammation, apoptosis, and other
clusters related to energy and bile acid homeostasis (Figure 5).
Remarkably, these networks included several Ppara target genes,
such as Cpt1a (AMI & TET), Mttp, Fabp, Acat1 (TET&VA), Fgf21
(AMI &VA), as well as processes that are governed by Ppara (e.g.
b-oxidation, lipid, and bile acid metabolism). Based on these
observations, we speculated that both AMI and VA act as Ppara
selective agonists, while TET could be an antagonist of Ppara.
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PPAR a, (b/d), and c Gene Reporter Assays
To assess whether the tested compounds act as PPARa agonists
or antagonist, we used a human stable PPARa gene reporter
assay, and also tested the same compounds in human PPAR b/d
and human PPAR c reporter assays to verify any possible
coactivity towards other members of closely related PPAR family.
The assays showed that VA is an agonist of PPAR a, b/d, and c
(Figure 6B, D, F). AMI was an agonist of PPARc (Figure 6G).
TET acted neither as an antagonist or agonist of any of the tested
PPARs (Figure S4).
Identification of Biomarkers
To identify candidate biomarkers for steatogenic drugs, we
focused on significant genes related to energy metabolism
extracted from the selected gene sets identified by GSEA, i.e.
glucose metabolism, lipid metabolism, fatty liver, peroxisomes,
mitochondrial diseases and drug metabolism (Figure 2). We tried
to distinguish between steatogenic compounds directly interfering
with PPARs, such as AMI and VA, and compounds acting like
TET. Therefore, as candidate biomarkers for PPAR agonists, we
tested 8 genes upregulated by both AMI and VA (Figure S5).
Although 2 out of the tested 8 genes were altered by all the studied
compounds, only AMI and VA upregulated these 2 genes, while
TET treatment led to their downregulation (Abcd3, Acat1). The 8
candidate biomarkers for PPAR agonists were subjected to HCA,
which led to a good separation between treatment and control for
AMI and VA (Figure 7 A–B). With respect to the identification of
candidate biomarkers for drugs acting similarly to TET, we
selected 77genes exclusively downregulated by this drug (Figure
S5). HCA was carried out for these 77 genes and eventually 19
genes leading to the best resolution between control and TET-
treated slices were selected (Figure 8C). More detailed information
on the functions of the candidate biomarkers is given in Table S3.
In order to check specificity of the selected genes to screen for
PPAR agonists or TET-like acting compounds, their expression
was analysed in slices treated with different classes of hepatotox-
icants, such as model cholestatic compounds (CsA, CPZ, and EE)
(Figures 7 D-F and 8 D–F), and model necrotic compounds
(APAP, ISND, and PQ) (Figures 7G-I and 8 G–I). With regard to
candidate biomarkers for drugs interfering with PPARs, we did not
detect a similar pattern of expression for any of the analysed
hepatotoxicants (Figure 7 D–I). With respect to candidate
biomarkers for TET-like drugs, only 2 of the tested hepatotox-
icants, i.e. CsA and CPZ, gave a similar gene expression pattern as
TET (Figure 8 D–E).
Comparative Data Analysis: Relevance for Mouse in vivo
and Human Primary Hepatocytes
To validate that mouse PCLS can be used as an alternative to
animal testing and it is a relevant model for the human situation to
study actions of model steatogenic compounds, another analysis
using publically available transcriptomics data was performed.
The data were derived from mouse livers and human primary
hepatocytes exposed to known PPAR agonists. In the in vivo
experiments, mice were treated with different PPARa agonists,
such as Wy14643 (for 5 days), fenofibrate and fish oil (for 14 days).
Primary human hepatocytes were exposed to Wy14643 for 6 and
24 h, as well as to double agonists of PPARa and PPARc, such as
aleglitazar, pioglitazone/fenofibrate, and tesaglitazar for 6 h.
GSEA showed that in all models, the known PPAR agonists
upregulated gene sets related to energy metabolism as well as
chronic and/or acute actions of Wy14643. Moreover, compounds
identified as PPAR agonists (AMI and VA) gave a similar results as
known PPAR agonists in gene sets related to lipid and energy
metabolism (Figure 9). In addition to the commonly regulated
gene sets by PPAR agonists, each of the analysed PPAR ligands
uniquely regulated other gene sets related to i.a. immunity or
morphogenesis. With regard to TET, next to mentioned above
downregulation of gene sets related to energy metabolism, it also
downregulated gene sets related to actions of Wy14643 (Figure 9).
Discussion
In this study we used mouse PCLS as an in vitro model to study
the mechanism of action of model steatogenic compounds. We
applied a toxicogenomics approach in combination with gene
reporter assays to examine the value of mouse PCLS as an
alternative to animal testing and relevant model for humans.
Effects on ATP content was used for dose selection since this is a
generally accepted assay for assessing slice viability. Based on the
ATP levels, none of the concentrations of the steatogenic drugs
affected viability in comparison to the controls (Figure 1). For the
gene expression profiling studies, 50, 200, and 40 mM for AMI,
VA, and TET were used similarly as in other studies [37–39].
Transcriptome data analysis including GSEA, GO analysis, and
functional clustering, showed that AMI and VA acted similarly,
indicating that these 2 drugs share some mechanisms of action.
GSEA and GO analysis identified that both drugs upregulated
processes related to lipid metabolism, and downregulated gene sets
and GO-terms related to diverse immune processes (Figure 2 A–B,
Figure S3, and Tables S2A–B). An additional gene functional
cluster analysis in STRING, showed that both AMI and VA
upregulated several clusters related to lipid homeostasis, such as
lipid synthesis or b-oxidation. These clusters contained known
PPARa target genes, exemplified by Pex11a, Elovl6, Pdk4, Cpt1a
and Cpt2 (upregulated by AMI) and Acsl1, Acox3, Mttp or Fabp4
(upregulated by VA treatment), Figures 3–4. These results agree
with the findings of others; in mouse liver AMI upregulated Acox2,
Cpt1, Cpt2 and Mttp, indicative of activation of lipid catabolism via
PPARa [16]. Gene expression profiles generated by VA in rat
hepatocytes and livers were highly similar to gene expression
profiles obtained with known PPARa agonists, thereby classifying
VA as a PPARa agonist [19]. However, our findings contrast to
those of others who found that AMI and VA toxicity is related to
the impairment of fatty acid b-oxidation after chronic treatment
[14,40,41]. This discrepancy may be caused by the different
duration used in these studies. AMI displays dual effects on
mitochondrial respiration characterized by an initial increased rate
of b-oxidation followed by a marked inhibition [42]. The duration
of 24 h we used may be too short to induce toxicity seen with
chronic exposure to AMI and VA in vivo [14,40,41]. Toxicity in
chronic exposure to AMI was caused by accumulation of its toxic
metabolites inhibiting mitochondrial proteins [42,43]. Similarly,
biotransformation of VA results in formation of 50 metabolites
that inhibit several enzymes of mitochondrial b-oxidation after
chronic treatment [17].
To determine whether the upregulation of PPARa target genes
was caused by direct binding of AMI and VA to PPARa, a PPARa
gene reporter assay was used. We also applied PPAR b/d and
PPAR c reporter assays, since several PPAR ligands are trans-
activating multiple forms of PPARs [18]. Indeed, VA not only
activated the PPARa reporter, but the b/d, and c assays, thereby
acting as a triple PPARa/(b/d)/c agonist (Figure 6 B, D, and G).
Activation of the PPARa reporter by VA agrees with findings that
it induces a gene expression pattern comparable to PPARa
agonists [19]. There seem to be no other reports on agonistic
effects of VA on PPARb/d or PPARc in the liver. Surprisingly,
Actions of Steatogenic Compounds in Liver Slices
PLOS ONE | www.plosone.org 12 January 2014 | Volume 9 | Issue 1 | e86795
AMI turned out to be a PPARc agonist instead of PPARa
agonists, as speculated based on our transcriptomics data and the
literature reports (Figure 6F) [16]. PPARc is highly expressed in
adipose tissue, where it controls adipogenesis and adipocyte
functions [44]. Under physiological conditions, PPARc has a low
expression in the liver, but has an elevated expression in the
steatotic liver [45]. Consistent with these notions, we observed that
some PPARc target genes involved in lipogenesis (Elovl6 and Fasn)
were upregulated by AMI. In addition, we observed upregulation
of genes involved in mitochondrial and peroxisomal b-oxidation
(Cpt1a, Cpt2, and Pex11a). These findings correspond with other
reports in which human and rat primary hepatocytes treated with
synthetic PPARc agonists upregulated the same genes [46,47].
We also found that AMI and VA downregulated several
processes related to inflammation and extracellular matrix. These
observations are in line with known anti-inflammatory and anti-
fibrotic actions of PPAR agonists on non-parenchymal liver cells
[18].
With regard to effects of TET on gene expression, GSEA and
GO analysis showed that TET downregulated processes related to
lipid metabolism (Figure 2 A–B). These results correspond with the
known negative interference of TET with mitochondrial b-
oxidation in rat liver associated with steatosis [8,48]. We also
found that TET downregulated expression of PPARa and its
target genes (e.g. Cpt1a, Fabp1; Figure 5), which agrees with
findings in the mouse liver [49]. However, it has been previously
shown that TET upregulated expression of lipogenic genes, such
as FASN, SREBP1C and PPARc, in the human HepaRG liver
cell line, which we did not find in mouse PCLS [37]. The
explanation for this difference could be related to inter-species
differences and/or the composition of both models. HepaRG
consists of hepatocyte-like cells, while PCLS contain parenchymal
and non-parenchymal cells, whose interactions are crucial for
regulation of lipid metabolism [18]. Moreover, in the mouse liver,
TET-induced steatosis has been associated with upregulation of
fatty acids elongases (Elovl 3, 5, 6) without altered expression of
other genes involved in de novo lipogenesis, such as FasN, Srebp1c,
and Pparc [9]. Therefore, steatogenic properties of TET seem to
be species- and model- specific and the underlying mechanism
requires additional studies. Furthermore, based on the outcome of
our PPAR assays, it can be concluded that the downregulation of
PPAR target genes is not related to direct antagonistic effects of
TET on any of the PPARs tested (Figure S4).
Since the outcome of our research points towards PPAR
agonistic activity of AMI and VA and negative regulation of lipid
metabolism by TET, we propose 2 dedicated sets of biomarkers
for PPAR agonists and TET-like acting compounds. Analysis of
candidate biomarkers for PPARs agonistic activity showed that the
selected genes were specifically upregulated by both AMI and VA
and were not altered by other types of hepatotoxicants (Figure 7
A–I). With regard to biomarkers for TET-like acting drugs, the
selected candidate genes separated TET-treated samples from
control slices but they did not separate slices treated with AMI,
VA, EE, as well as necrotic compounds. Remarkably, the
biomarker genes for TET were also downregulated by CsA and
CPZ (Figure 8 D–E). This indicates that TET shares mechanism
of action with CsA and CPZ, which both negatively affect
mitochondrial activity by induction of oxidative stress [50,51].
Although CsA and CPZ have been regarded here as model
cholestatic compounds, they can also cause steatosis, likely by
impairment of mitochondrial functions [52–55].
Comparative analysis of gene expression patterns in mouse
PCLS exposed to steatogenic drugs versus human primary
hepatocytes and livers of mice exposed to known PPAR agonists
clearly showed similarities in regulation of gene sets related to lipid
metabolism and PPAR signaling. This supports the use of mouse
PCLS as an alternative to animal testing and human in vitromodels
for the identification of early mechanisms involved in drug-
induced perturbations in lipid homeostasis (Figure 9).
In summary, mouse PCLS in combination with transcriptomics,
can be used to study early mechanisms of action induced by model
steatogenic drugs. Both AMI and VA affect processes related to
lipid metabolism by binding to master regulators of lipid
homeostasis, i.e. PPARc and PPARa/(b/d)/c respectively and
regulating expression of their target genes. TET downregulated
processes related to mitochondrial functions and lipid metabolism.
Regarding the comparative GSEA analysis, the results obtained in
mouse PCLS are alike with mouse in vivo and human in vitro data,
supporting mouse PCLS as a good alternative to animal testing
and a valid model to study effects of steatogenic compounds in
relation to the human situation. Two sets of the identified
candidate biomarkers could be used to screen for compounds that
alter lipid metabolism and as such may be hepatotoxic.
Supporting Information
Figure S1 Dose selection experiments for cholestatic
and necrotic drugs. Liver slices were incubated for 24 h with a
range of concentrations for model cholestatic compounds:
cyclosporin A (CsA) 1–100 mM, chlorpromazine (CPZ) 2–
80 mM, ethinyl estradiol (EE) 0.1–100 mM, and model necrotic
compounds: acetaminophen (APAP) 0.3–3 mM, isoniazid (ISND)
0.1–1 mM, paraquat (PQ) 1–10 mM, or corresponding controls.
ATP content (nmol/mg of protein) was measured to assess liver
slice viability. Each point is the mean6SD of 2 independent
experiments (liver slices were isolated from livers of 2 mice) and
each measurement was done in duplicate.
(PPTX)
Figure S2 Viability of mouse liver slices upon treatment
with cholestatic and necrotic drugs. Liver slices were
incubated for 24 h with pre-selected concentrations of model
cholestatic compounds: cyclosporin A (CsA) 40 mM, chlorprom-
azine (CPZ) 20 mM, ethinyl estratiol (EE) 10 mM, and model
necrotic compounds: acetaminophen (APAP), isoniazid (ISND),
paraquat (PQ), or corresponding controls (ctr). ATP content
(nmol/mg of protein) was measured to assess liver slice viability.
Each point is the mean6SD of 5 independent experiments (liver
slices were isolated from livers of 5 mice) and each measurement
was done in duplicate. Slices viability was not significantly affected
by any of the tested drug concentrations compared to control.
(PPTX)
Figure S3 Comparative analysis of significant genes
and GO processes affected by steatogenic drugs in
mouse PCLS. (A) Genes identified by GSEA as being
significantly altered in PCLS upon amiodarone (AMI), valproic
acid (VA), and tetracycline (TET) are shown as Venn diagrams.
(B) The same genes were used for Gene Ontology (GO) analysis in
DAVID and the significant GO terms (p,0.05, FDR,0.005) are
shown in Venn diagrams.
(PPTX)
Figure S4 Effect of tetracycline on PPARa-, PPAR b/d-,
and PPARc gene reporter assays. Luciferase activity of
PPARa-, PPAR b/d-, and PPARc- CALUX cells on exposure to
corresponding agonists GW7647 (A), L-165, 041 (D), and
rosiglitazone (G) respectively. Tetracycline (TET) was tested in
both agonistic (B, E, H) and antagonistic (C, F, I) modes in the 3
PPAR-CALUX assays. Data are corrected for solvent control
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values and are expressed as means6standard errors (n = 3). X axis
represents concentration of the tested compounds [M] and y axis
represents luciferase units.
(PPTX)
Figure S5 Identification of candidate biomarkers for
steatogenic drugs in mouse PCLS. To identify candidate
biomarkers for steatogenic drugs, significant genes found by GSEA
in precision cut liver slices (PCLS) treated with amiodarone (AMI),
valproic acid (VA), and tetracycline (TET) were analysed by Venn
diagrams. Eight overlapping, upregulated genes in PCLS treated
with AMI and VA were considered as candidate biomarkers for
PPARs agonists. Genes uniquely downregulated by TET (i.e. 77),
were considered as candidate biomarkers for TET-like acting
compounds.
(PPTX)
Table S1 ANNI gene sets. Gene sets related to diverse hepatic
and non-hepatic functions were created in ANNI and were used in
GSEA to detect major biological processes affected by treatment
with amiodarone, valproic acid, and tetracycline.
(DOCX)
Table S2 Total GO analysis. Significant genes altered by
steatogenic drugs in precision cut liver slices (PCLS) were
subjected to Gene Ontology (GO) analysis in DAVID. The GO
analysis identified 288 (27 up- and 261-down-regulated), 152 (18
up- and 136 down-regulated), and 21 (downregulated) GO terms
for amiodarone, valproic acid, and tetracycline respectively.
(DOCX)
Table S3 Candidate biomarkers. Functions of candidate
biomarkers for PPAR agonists and tetracycline (TET)-like acting
compounds are derived from GeneCards http://www.genecards.
org.
(DOCX)
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